1st Circ. Won't Rethink Ending Sarepta Securities Suit

Law360, Washington (October 12, 2017, 2:06 PM EDT) -- The First Circuit refused Wednesday to reconsider its August decision upholding the dismissal of a putative securities class action accusing drugmaker Sarepta Therapeutics Inc. of misleading investors over the possibility of government approval for its muscular dystrophy drug eteplirsen.

The court issued a single-paragraph decision stating the denial of rehearing by the initial panel that shot down the investors’ appeal, as well as the refusal by “a majority of the judges” of the full circuit to take on the case. Tuesday’s refusal leaves intact the August ruling...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Corban, et al v. Sarepta Therapeutics, Inc., et al


Case Number

16-1658

Court

Appellate - 1st Circuit

Nature of Suit

3850 Securities/Commodities/Exchange

Date Filed

May 31, 2016

Law Firms

Companies

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.